Overview

Update
IPO / Stock
Went Public on Feb 13, 2014 / NASDAQ:CNCE
Total Equity Funding
$99.5M in 4 Rounds from 13 Investors
Headquarters:
Lexington, Massachusetts
Description:
Concert Pharmaceuticals is a biotechnology company utilizing deuterium to develop novel medical candidates.
Founders:
,
Categories:
Health Care, Biotechnology, Medical
Website:
http://www.concertpharma.com
Social:

Company Details

Update

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.

Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

Funding Rounds (4) - $99.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2011$4M / Venture1
Apr, 2008$37M / Series C12
Nov, 2006$48.5M / Series B8
Jul, 2006$10M / Series A5

Current Team (5)

Update

Offices/Locations (1)

Update
  • Headquarters

    99 Hayden Avenue

    Suite 500

    Lexington, Massachusetts 02421

    United States

Past Team (3)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos